Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 14, 2024	Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused	View HTML PDF Version
Toggle Summary Mar 07, 2024	Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 SOLANA BEACH, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to	View HTML PDF Version
Toggle Summary Feb 14, 2024	Evoke Pharma Announces Closing of $7.5 Million Public Offering Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an	View HTML PDF Version
Toggle Summary Feb 09, 2024	Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has priced an	View HTML PDF Version
Toggle Summary Nov 27, 2023	Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®	View HTML PDF Version
Toggle Summary Nov 14, 2023	United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®	View HTML PDF Version
Toggle Summary Nov 09, 2023	Evoke Pharma Reports Third Quarter 2023 Financial Results 38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in	View HTML PDF Version
Toggle Summary Oct 31, 2023	Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023 Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide SOLANA BEACH, Calif. , Oct.	View HTML PDF Version
Toggle Summary Oct 18, 2023	Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An Selected for a Distinguished Oral Plenary Presentation SOLANA BEACH, Calif. , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)	View HTML PDF Version
Toggle Summary Sep 14, 2023	Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI® SOLANA BEACH, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it has been granted a	View HTML PDF Version